Categories: Health

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.

The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.

The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.



GlobeNews Wire

Recent Posts

Bybit Launches IPO Express, Becoming One of First Centralized Crypto Exchanges to Offer Tokenized IPO Access, Starting With SpaceX

DUBAI, UAE, June 7, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading…

10 hours ago

Astrall Dynamics Makes INTERSCHUTZ 2026 Debut with Hypertron-T01 Quadruped Firefighting Robot

HANOVER, Germany, June 07, 2026 (GLOBE NEWSWIRE) -- Astrall Dynamics demonstrated its Hypertron-T01 heavy-duty quadruped…

13 hours ago

Astrall Dynamics Showcases Unmanned Quadruped Firefighting Robot at INTERSCHUTZ 2026

HANOVER, Germany, June 07, 2026 (GLOBE NEWSWIRE) -- Astrall Dynamics at INTERSCHUTZ 2026’s debut demonstrated…

13 hours ago

Astrall Dynamics Unveils Integrated Quadruped Firefighting Robot Hypertron-T01 at INTERSCHUTZ 2026

HANOVER, Germany, June 07, 2026 (GLOBE NEWSWIRE) -- Astrall Dynamics unveiled the Hypertron-T01 firefighting robot…

13 hours ago

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the…

13 hours ago

Vireo Growth Inc. Completes Acquisition of Bridgewell Agribusiness LLC and Plans to Acquire Dispensaries in Nevada and Maryland

MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo”…

13 hours ago